Nano-hydroxyapatite Toothpaste for Dentin Hypersensitivity Relief
This study aims to evaluate the effectiveness of nano-hydroxyapatite toothpaste in reducing pain intensity for adults experiencing dentin hypersensitivity.
Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste
+ Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste
Dentin Sensitivity
+ Stomatognathic Diseases
+ Tooth Diseases
Treatment Study
Summary
Study start date: July 1, 2024
Actual date on which the first participant was enrolled.This study is exploring a new toothpaste containing nano-hydroxyapatite (n-HAp) to help adults with sensitive teeth, a condition known as dentin hypersensitivity. The n-HAp particles are incredibly small and similar to the natural minerals found in teeth. They are designed to penetrate the tiny channels in teeth that cause sensitivity, potentially blocking them and reducing discomfort. The study aims to test how effective this toothpaste is, which could offer a new way to relieve the pain often experienced by those with sensitive teeth. Participants in the study use the toothpaste containing n-HAp as directed. Researchers observe how well the toothpaste works in reducing dental sensitivity by examining changes in discomfort levels. The particles in the toothpaste aim to act like fillers, entering the channels in the teeth and stopping the movement of fluid, which is what typically causes the sensitivity. This study does not list specific outcomes or risks, but it is a Phase 1 trial, indicating early-stage testing of the product's safety and potential benefits.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.39 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorGroup II
ExperimentalGroup III
ExperimentalStudy Objectives
Primary Objectives